BACKGROUND: The AS04-adjuvanted HPV16/18 (AS04-HPV16/18) vaccine provides excellent protection against targeted human papillomavirus (HPV) types and a variable degree of cross-protection against others, including types 6/11/31/33/45. High efficacy against any cervical intraepithelial neoplasia grade 3 or greater (CIN3+; >90%) suggests that lower levels of protection may exist for a wide range of oncogenic HPV types, which is difficult to quantify in individual trials. Pooling individual-level data from two randomized controlled trials, we aimed to evaluate AS04-HPV16/18 vaccine efficacy against incident HPV infections and cervical abnormalities . METHODS: Data were available from the Costa Rica Vaccine Trial (NCT00128661) and Papilloma Trial Against Cancer in Young Adults trial (NCT00122681), two large-scale, double-blind randomized controlled trials of the AS04-HPV16/18 vaccine. Primary analyses focused on disease-free women with no detectable cervicovaginal HPV at baseline. RESULTS:A total of 12 550 women were included in our primary analyses (HPV arm = 6271, control arm = 6279). Incidence of 6-month persistent oncogenic and nononcogenic infections, excluding known and accepted protected types 6/11/16/18/31/33/45 (focusing on 34/35/39/40/42/43/44/51/52/53/54/56/58/59/66/68/73/70/74), was statistically significantly lower in the HPV arm than in the control arm (efficacy = 9.9%, 95% confidence interval [CI] = 1.7% to 17.4%). Statistically significant efficacy (P < .05) was observed for individual oncogenic types 16/18/31/33/45/52 and nononcogenic types 6/11/53/74. Efficacy against cervical abnormalities (all types) increased with severity, ranging from 27.7% (95% CI = 21.7% to 33.3%) to 58.7% (95% CI = 34.1% to 74.7%) for cytologic outcomes (low-grade squamous intraepithelial neoplasia lesion or greater, and high-grade squamous intraepithelial neoplasia lesion or greater, respectively) and 66.0% (95% CI = 54.4% to 74.9%) to 87.8% (95% CI = 71.1% to 95.7%) for histologic outcomes (CIN2+ and CIN3+, respectively). Comparing Costa Rica Vaccine Trial and Papilloma Trial Against Cancer in Young Adults results, there was no evidence of heterogeneity, except for type 51 (efficacy = -28.6% and 20.7%, respectively; two-sided P = .03). CONCLUSIONS: The AS04-HPV16/18 vaccine provides some additional cross-protection beyond established protected types, which partially explains the high efficacy against CIN3+. Published by Oxford University Press 2019. This work is written by US Government employees and is in the public domain in the US.
RCT Entities:
BACKGROUND: The AS04-adjuvanted HPV16/18 (AS04-HPV16/18) vaccine provides excellent protection against targeted human papillomavirus (HPV) types and a variable degree of cross-protection against others, including types 6/11/31/33/45. High efficacy against any cervical intraepithelial neoplasia grade 3 or greater (CIN3+; >90%) suggests that lower levels of protection may exist for a wide range of oncogenic HPV types, which is difficult to quantify in individual trials. Pooling individual-level data from two randomized controlled trials, we aimed to evaluate AS04-HPV16/18 vaccine efficacy against incident HPV infections and cervical abnormalities . METHODS: Data were available from the Costa Rica Vaccine Trial (NCT00128661) and Papilloma Trial Against Cancer in Young Adults trial (NCT00122681), two large-scale, double-blind randomized controlled trials of the AS04-HPV16/18 vaccine. Primary analyses focused on disease-free women with no detectable cervicovaginal HPV at baseline. RESULTS: A total of 12 550 women were included in our primary analyses (HPV arm = 6271, control arm = 6279). Incidence of 6-month persistent oncogenic and nononcogenic infections, excluding known and accepted protected types 6/11/16/18/31/33/45 (focusing on 34/35/39/40/42/43/44/51/52/53/54/56/58/59/66/68/73/70/74), was statistically significantly lower in the HPV arm than in the control arm (efficacy = 9.9%, 95% confidence interval [CI] = 1.7% to 17.4%). Statistically significant efficacy (P < .05) was observed for individual oncogenic types 16/18/31/33/45/52 and nononcogenic types 6/11/53/74. Efficacy against cervical abnormalities (all types) increased with severity, ranging from 27.7% (95% CI = 21.7% to 33.3%) to 58.7% (95% CI = 34.1% to 74.7%) for cytologic outcomes (low-grade squamous intraepithelial neoplasia lesion or greater, and high-grade squamous intraepithelial neoplasia lesion or greater, respectively) and 66.0% (95% CI = 54.4% to 74.9%) to 87.8% (95% CI = 71.1% to 95.7%) for histologic outcomes (CIN2+ and CIN3+, respectively). Comparing Costa Rica Vaccine Trial and Papilloma Trial Against Cancer in Young Adults results, there was no evidence of heterogeneity, except for type 51 (efficacy = -28.6% and 20.7%, respectively; two-sided P = .03). CONCLUSIONS: The AS04-HPV16/18 vaccine provides some additional cross-protection beyond established protected types, which partially explains the high efficacy against CIN3+. Published by Oxford University Press 2019. This work is written by US Government employees and is in the public domain in the US.
Authors: Matti Lehtinen; Jorma Paavonen; Cosette M Wheeler; Unnop Jaisamrarn; Suzanne M Garland; Xavier Castellsagué; S Rachel Skinner; Dan Apter; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Henry Kitchener; Júlio C Teixeira; James Hedrick; Genara Limson; Anne Szarewski; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; Newton S De Carvalho; Maria Julieta V Germar; Klaus Peters; Adrian Mindel; Philippe De Sutter; F Xavier Bosch; Marie-Pierre David; Dominique Descamps; Frank Struyf; Gary Dubin Journal: Lancet Oncol Date: 2011-11-08 Impact factor: 41.316
Authors: Brooke Bishop; Jhimli Dasgupta; Michael Klein; Robert L Garcea; Neil D Christensen; Rui Zhao; Xiaojiang S Chen Journal: J Biol Chem Date: 2007-09-04 Impact factor: 5.157
Authors: Joseph E Tota; Agnihotram V Ramanakumar; Mengzhu Jiang; Joakim Dillner; Stephen D Walter; Jay S Kaufman; François Coutlée; Luisa L Villa; Eduardo L Franco Journal: Am J Epidemiol Date: 2013-05-09 Impact factor: 4.897
Authors: Rolando Herrero; Sholom Wacholder; Ana C Rodríguez; Diane Solomon; Paula González; Aimee R Kreimer; Carolina Porras; John Schussler; Silvia Jiménez; Mark E Sherman; Wim Quint; John T Schiller; Douglas R Lowy; Mark Schiffman; Allan Hildesheim Journal: Cancer Discov Date: 2011-09-09 Impact factor: 39.397
Authors: Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Cosette M Wheeler; Song-Nan Chow; Dan L Apter; Henry C Kitchener; Xavier Castellsague; Newton S de Carvalho; S Rachel Skinner; Diane M Harper; James A Hedrick; Unnop Jaisamrarn; Genara Am Limson; Marc Dionne; Wim Quint; Bart Spiessens; Pascal Peeters; Frank Struyf; Susan L Wieting; Matti O Lehtinen; Gary Dubin Journal: Lancet Date: 2007-06-30 Impact factor: 79.321
Authors: Kimberley Kavanagh; Kevin G Pollock; Kate Cuschieri; Tim Palmer; Ross L Cameron; Cameron Watt; Ramya Bhatia; Catherine Moore; Heather Cubie; Margaret Cruickshank; Chris Robertson Journal: Lancet Infect Dis Date: 2017-09-28 Impact factor: 25.071
Authors: Sabrina H Tsang; Joshua N Sampson; John Schussler; Carolina Porras; Sarah Wagner; Joseph Boland; Bernal Cortes; Douglas R Lowy; John T Schiller; Mark Schiffman; Troy J Kemp; Ana Cecilia Rodriguez; Wim Quint; Mitchell H Gail; Ligia A Pinto; Paula Gonzalez; Allan Hildesheim; Aimée R Kreimer; Rolando Herrero Journal: J Natl Cancer Inst Date: 2020-10-01 Impact factor: 13.506
Authors: Joseph E Tota; Frank Struyf; Allan Hildesheim; Paula Gonzalez; Martin Ryser; Rolando Herrero; John Schussler; Naveen Karkada; Ana Cecilia Rodriguez; Nicolas Folschweiller; Carolina Porras; Mark Schiffman; John T Schiller; Wim Quint; Aimée R Kreimer; Matti Lehtinen; Cosette M Wheeler; Joshua N Sampson Journal: J Infect Dis Date: 2021-05-20 Impact factor: 5.226